<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711308</url>
  </required_header>
  <id_info>
    <org_study_id>EX0401ES</org_study_id>
    <secondary_id>eudract-no. 2004-002019-97</secondary_id>
    <nct_id>NCT00711308</nct_id>
  </id_info>
  <brief_title>Tinzaparin in the Treatment of the Acute Pulmonary Embolism</brief_title>
  <official_title>Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complejo Hospitalario Xeral-Calde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Complejo Hospitalario Xeral-Calde</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility of the long-term treatment of&#xD;
      pulmonary embolism with tinzaparin compared to oral anticoagulants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The open-label prospective randomized clinical trial compares subcutaneous LMWH (tinzaparin)&#xD;
      administered for 6 months versus initial treatment using subcutaneous LMWH followed by oral&#xD;
      anticoagulants given for 6 months in patients with acute venous thrombosis.&#xD;
&#xD;
      To evaluate the direct and indirect cost of each treatment regimen in a rural population&#xD;
      environment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the secondary prophylaxis of pulmonary embolism with tinzaparin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>direct and indirect cost of each treatment regimen</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major haemorrhagic events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Acute Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>tinzaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acenocoumarol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tinzaparin followed by acenocoumarol for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tinzaparin</intervention_name>
    <description>tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months</description>
    <arm_group_label>acenocoumarol</arm_group_label>
    <arm_group_label>tinzaparin</arm_group_label>
    <other_name>innohep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acenocoumarol</intervention_name>
    <description>acenocoumarol for 6 months</description>
    <arm_group_label>acenocoumarol</arm_group_label>
    <other_name>vitamin K antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic pulmonary embolism patients confirmed by:&#xD;
&#xD;
               -  High probability ventilation/perfusion lung scan according to the PIOPED criteria&#xD;
&#xD;
               -  Spiral chest computed tomography, or&#xD;
&#xD;
               -  Pulmonary arteriography&#xD;
&#xD;
          -  Aged 18 years or above, of either sex&#xD;
&#xD;
          -  The patient must provide signed informed consent&#xD;
&#xD;
          -  Patients will be agreed for receiving ambulatory anticoagulant treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Massive pulmonary embolism&#xD;
&#xD;
          -  Allergy to heparin, other components of Tinzaparin or acenocoumarol&#xD;
&#xD;
          -  Previous thrombocytopenia induced by heparin&#xD;
&#xD;
          -  Thrombocytopenia &lt; 100000/mm3&#xD;
&#xD;
          -  History/signs/symptoms of congenital bleeding disorder&#xD;
&#xD;
          -  Life expectancy less than 90 days&#xD;
&#xD;
          -  Unfractioned heparin anticoagulation for more than 36 hours prior enrollment&#xD;
&#xD;
          -  Inability to participate in the home tinzaparin program&#xD;
&#xD;
          -  Clinical overt gastrointestinal blood loss due to peptic ulcer, intestinal tumours,&#xD;
             oesophagitis or diverticulosis&#xD;
&#xD;
          -  Hemoglobin lower than 7 g/dL or Creatinin &gt; 3mg/dL&#xD;
&#xD;
          -  Cerebral-vascular accident&#xD;
&#xD;
          -  Cerebral, medullary and ophthalmological surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Pérez de Llano, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Complejo Hospitalario Xeral Calde (Lugo)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Veres Racamonde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Xeral Calde (Lugo)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Núnez Delgado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Meixoeiro (Vigo)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Palacios Bartolomé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Virginia Leiro Fernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Xeral (Vigo)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pneumology Service. Hospital Clínico</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumology Service. Hospital Xeral Cies</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumology Service. Hospital do Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36214</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumology Service</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2008</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pérez de Llano, Luis MD</name_title>
    <organization>Pneumology Service, Complejo Hospitalario Xeral-Calde</organization>
  </responsible_party>
  <keyword>pulmonary embolism</keyword>
  <keyword>low molecular weight heparin</keyword>
  <keyword>vitamin K antagonist</keyword>
  <keyword>Longterm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

